Ligand Pharmaceuticals Signs License Agreement With Avion Pharmaceuticals, LLC

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its signing of a commercial license agreement for the development and commercialization for four Captisol-enabled programs with Avion Pharmaceuticals, LLC. Pursuant to the agreement, Ligand will receive an up-front payment and is also eligible to receive revenue from Captisol material sales, milestone payments, and royalties on future net sales.

Avion Pharmaceuticals focuses on developing and marketing pharmaceutical and dietary supplement products in women’s health and dermatology. Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Read the press release.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.